Clinical trial

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

NCT07513168

Study summary

ClinicalTrials.gov

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-08-01

PhasePHASE4

Conditions

Obesityverified · MONDO: obesity disorder

Weight Reductionunresolved

Cardiometabolic Risk Factorsunresolved

Interventions

Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)DRUG

Sponsors & collaborators

Asian Institute Of Medical Scienceslead sponsor

Mapped research locations

HyderābādSindh, Pakistan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07513168 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.